Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical…
Biotechnology
US, Pittsburgh [HQ]
KRYS/Financial Reporting
Income Statements
8 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | - - | 1.00 | - - | - - | - - | - - | 50.00 | |
|
EPS
|
-0.27 | -1.48 | -0.97 | -1.20 | -1.71 | -3.13 | -5.49 | 0.40 | |
| Diluted in mil. | -0.27 | -1.48 | -0.97 | -1.20 | -1.71 | -3.13 | -5.49 | 0.39 | |
|
Profit
|
- - | - - | 1.00 | - - | -1.00 | -2.00 | -4.00 | 42.00 | |
| Gross Margin | - - | - - | 100.00 | - - | - - | - - | - - | 84.02 | |
| Pre Tax | -1.00 | -7.00 | -10.00 | -19.00 | -32.00 | -69.00 | -139.00 | 12.00 | |
| Profit Margin | - - | - - | -1,060.27 | - - | - - | - - | - - | 25.44 | |
| ETR | - - | - - | - - | - - | - - | - - | - - | 15.24 | |
| Net | -1.00 | -7.00 | -10.00 | -19.00 | -32.00 | -69.00 | -139.00 | 10.00 | |
| Profit Margin | - - | - - | -1,060.27 | - - | - - | - - | - - | 21.56 | |
| EBITDA | -1.00 | -4.00 | -11.00 | -21.00 | -31.00 | -65.00 | -110.00 | -92.00 | |
| EBITDA Margin | - - | - - | -1,146.54 | - - | - - | - - | - - | -181.90 | |
| Operating Income | -1.00 | -4.00 | -11.00 | -22.00 | -32.00 | -68.00 | -145.00 | -97.00 | |
| Operating Margin | - - | - - | -1,160.27 | - - | - - | - - | - - | -191.77 | |
| Interest Income | - - | - - | - - | 2.00 | - - | - - | 5.00 | 22.00 | |
| Loss | -1.00 | -4.00 | -11.00 | -22.00 | -32.00 | -68.00 | -120.00 | -147.00 | |
| Cost of Revenue | - - | - - | - - | - - | -1.00 | -2.00 | -4.00 | -8.00 | |
|
Operating Expenses
|
-1.00 | -4.00 | -11.00 | -22.00 | -32.00 | -68.00 | -120.00 | -139.00 | |
| R&D | - - | -3.00 | -7.00 | -15.00 | -17.00 | -27.00 | -42.00 | -46.00 | |
| G&A | - - | -1.00 | -4.00 | -6.00 | -15.00 | -40.00 | -77.00 | - - | |
| SG&A | - - | -1.00 | -4.00 | -6.00 | -15.00 | -40.00 | -77.00 | -93.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | |
| Depreciation and Amortization | - - | - - | - - | - - | -1.00 | -2.00 | -4.00 | -5.00 | |
| Interest Expenses | - - | -3.00 | -1.00 | - - | - - | -1.00 | -5.00 | - - | |
| Other Expenses | - - | -3.00 | -1.00 | -2.00 | - - | -1.00 | -5.00 | -110.00 | |
|
WA Shares Outstanding
|
4.00 | 5.00 | 11.00 | 15.00 | 18.00 | 22.00 | 25.00 | 27.00 | |
| Diluted | 4.00 | 5.00 | 11.00 | 15.00 | 18.00 | 22.00 | 25.00 | 27.00 |